Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...
The "direct-to-watch" feature eliminates the need to keep your phone near for readings. Dexcom is looking into other smartwatches too, the company's COO says. Dexcom G7, a continuous glucose ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It’s the longest-lasting wearable on the market. The G7 15 ...
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
Diabetes tracker developer Dexcom is pushing back the timeline for a U.S. launch of the latest generation of its continuous glucose monitor, the G7, after the FDA raised questions about the device’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results